Weijun Gu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Weijun Gu has a total of 191 co-authors. Here are the top co-authors by number of shared publications:
- Yiming Mu
Department of Endocrinology The First Medical Center of PLA General Hospital Beijing China
39 shared publications - Jing-Tao Dou
Department of Endocrinology, Chinese PLA General Hospital, Beijing, China
16 shared publications Jin Du
Department of Endocrinology, the First Medical Center of Chinese People’s Liberation Army General Hospital, Beijing, China
14 shared publicationsGuoqing Yang
Department of Endocrinology, Hainan Hospital of Chinese PLA General Hospital, Sanya, Hainan, China, 301hospital.com.cn
13 shared publicationsLi Zang
Department of Endocrinology The First Medical Center of Chinese PLA General Hospital Beijing China
13 shared publications- Jianming Ba
Department of Endocrinology, Chinese PLA General Hospital, Beijing 100853, China
12 shared publications
Latest Publications
- Open Access
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
KCTD8–GABAB2 Protein Complex Drives Β-Catenin Activation, Tumour Invasion, And Immune Suppression In Pituitary Neuroendocrine Tumours
Background: Invasive pituitary neuroendocrine tumours (PitNETs) are clinically challenging because local invasion compromises complete resection and increases the risk of recurrence. Here, we aimed to gain insight into the mechanisms of invasive PitNET progression driven by the KCTD8–GABAB2 protein complex.Methods: Bulk and single-nucleus transcriptomic analyses, clinical validation, functional assays, immune co-culture systems, patient-derived organoids, and xenograft models were integrated to define KCTD8-associated invasive mechanisms in PitNETs.Findings: Invasive PitNETs displayed distinct GABA-associated transcriptional programmes that were primarily localised to pituitary tumour cells. Integrative transcriptomic analyses identified KCTD8 as an invasion-associated molecule enriched in invasive tumour-cell states. High KCTD8 expression was associated with aggressive clinicopathological features and shorter recurrence-free survival. Mechanistically, KCTD8 formed a protein complex with GABAB2 and promoted β-catenin accumulation and nuclear translocation, thereby enhancing tumour-cell stemness, invasion, and clonogenic growth. Genetic or pharmacological blockade of GABAB receptor signalling attenuated KCTD8-induced β-catenin activation and aggressive phenotypes. KCTD8 also induced a CCL2/CCL5-dependent immunosuppressive programme, promoting M2-like macrophage polarisation and CD8+ T-cell dysfunction. Pharmacological intervention with capmatinib, a repurposing candidate identified through in silico screening, suppressed patient-derived PitNET organoid growth and inhibited tumour progression while remodelling the immune microenvironment in xenograft models.Interpretation: The KCTD8–GABAB2 axis links neurotransmitter-receptor signalling to β-catenin-dependent tumour-cell plasticity and CCL2/CCL5-mediated immune suppression in invasive PitNETs. This axis represents a potential biomarker of aggressive disease and a candidate therapeutic vulnerability that warrants further preclinical and clinical validation.Funding: This research was supported by the National Natural Science Foundation of China (Grant No. 82503954), Beijing Natural Science Foundation (Grant No. QG26019), and the China Postdoctoral Science Foundation (Grant No. 2024M750130).
- 9 October 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessKCTD8–GABAB2 Protein Complex Drives Β-Catenin Activation, Tumour Invasion, And Immune Suppression In Pituitary Neuroendocrine Tumours
Background: Invasive pituitary neuroendocrine tumours (PitNETs) are clinically challenging because local invasion compromises complete resection and increases the risk of recurrence. Here, we aimed to gain insight into the mechanisms of invasive PitNET progression driven by the KCTD8–GABAB2 protein complex.Methods: Bulk and single-nucleus transcriptomic analyses, clinical validation, functional assays, immune co-culture systems, patient-derived organoids, and xenograft models were integrated to define KCTD8-associated invasive mechanisms in PitNETs.Findings: Invasive PitNETs displayed distinct GABA-associated transcriptional programmes that were primarily localised to pituitary tumour cells. Integrative transcriptomic analyses identified KCTD8 as an invasion-associated molecule enriched in invasive tumour-cell states. High KCTD8 expression was associated with aggressive clinicopathological features and shorter recurrence-free survival. Mechanistically, KCTD8 formed a protein complex with GABAB2 and promoted β-catenin accumulation and nuclear translocation, thereby enhancing tumour-cell stemness, invasion, and clonogenic growth. Genetic or pharmacological blockade of GABAB receptor signalling attenuated KCTD8-induced β-catenin activation and aggressive phenotypes. KCTD8 also induced a CCL2/CCL5-dependent immunosuppressive programme, promoting M2-like macrophage polarisation and CD8+ T-cell dysfunction. Pharmacological intervention with capmatinib, a repurposing candidate identified through in silico screening, suppressed patient-derived PitNET organoid growth and inhibited tumour progression while remodelling the immune microenvironment in xenograft models.Interpretation: The KCTD8–GABAB2 axis links neurotransmitter-receptor signalling to β-catenin-dependent tumour-cell plasticity and CCL2/CCL5-mediated immune suppression in invasive PitNETs. This axis represents a potential biomarker of aggressive disease and a candidate therapeutic vulnerability that warrants further preclinical and clinical validation.Funding: This research was supported by the National Natural Science Foundation of China (Grant No. 82503954), Beijing Natural Science Foundation (Grant No. QG26019), and the China Postdoctoral Science Foundation (Grant No. 2024M750130).
- Open Access
- 19 July 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (10) , 9091-9100
Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study
Aims: To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by baseline age, Type 2 diabetes (T2D) duration and glycated haemoglobin (HbA1c) in the Soli‐D study. Materials and Methods: In Soli‐D, Chinese adults with T2D suboptimally controlled on oral antidiabetic drugs (OADs) were randomized to iGlarLixi or IDegAsp for 24 weeks. These post hoc analyses evaluated glycaemic efficacy, insulin dose, body weight and hypoglycaemia outcomes in subgroups defined by baseline age (< 65, ≥ 65 years), T2D duration (< 10, ≥ 10 years) and HbA1c (≥ 7% to ≤ 8% [≥ 53 to ≤ 64 mmol/mol], > 8% to ≤ 9% [> 64 to ≤ 75 mmol/mol], > 9% [> 75 mmol/mol]). Results: Among 582 participants (iGlarLixi n = 291; IDegAsp n = 291), baseline age was < 65 years in 442 and ≥ 65 years in 140; T2D duration was < 10 years in 366 and ≥ 10 years in 216; and HbA1c was ≥ 7% to ≤ 8% in 205, > 8% to ≤ 9% in 209 and > 9% in 168. At Week 24, HbA1c reductions were greater with iGlarLixi versus IDegAsp, with no treatment‐by‐subgroup interactions for baseline age, T2D duration or HbA1c. Change in other glycaemic outcomes, insulin dose and body weight generally showed no interaction across subgroups. Total insulin daily doses during treatment and hypoglycaemia event rates were consistently lower with iGlarLixi versus IDegAsp in all subgroups. Conclusions: iGlarLixi provides improved glycaemic control at lower insulin doses with reduced risk of hypoglycaemia in Chinese adults with suboptimally controlled T2D on OADs, regardless of baseline age, disease duration or HbA1c.
- 19 July 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (10) , 9091-9100
Open AccessEfficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli‐D Study
Aims: To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by baseline age, Type 2 diabetes (T2D) duration and glycated haemoglobin (HbA1c) in the Soli‐D study. Materials and Methods: In Soli‐D, Chinese adults with T2D suboptimally controlled on oral antidiabetic drugs (OADs) were randomized to iGlarLixi or IDegAsp for 24 weeks. These post hoc analyses evaluated glycaemic efficacy, insulin dose, body weight and hypoglycaemia outcomes in subgroups defined by baseline age (< 65, ≥ 65 years), T2D duration (< 10, ≥ 10 years) and HbA1c (≥ 7% to ≤ 8% [≥ 53 to ≤ 64 mmol/mol], > 8% to ≤ 9% [> 64 to ≤ 75 mmol/mol], > 9% [> 75 mmol/mol]). Results: Among 582 participants (iGlarLixi n = 291; IDegAsp n = 291), baseline age was < 65 years in 442 and ≥ 65 years in 140; T2D duration was < 10 years in 366 and ≥ 10 years in 216; and HbA1c was ≥ 7% to ≤ 8% in 205, > 8% to ≤ 9% in 209 and > 9% in 168. At Week 24, HbA1c reductions were greater with iGlarLixi versus IDegAsp, with no treatment‐by‐subgroup interactions for baseline age, T2D duration or HbA1c. Change in other glycaemic outcomes, insulin dose and body weight generally showed no interaction across subgroups. Total insulin daily doses during treatment and hypoglycaemia event rates were consistently lower with iGlarLixi versus IDegAsp in all subgroups. Conclusions: iGlarLixi provides improved glycaemic control at lower insulin doses with reduced risk of hypoglycaemia in Chinese adults with suboptimally controlled T2D on OADs, regardless of baseline age, disease duration or HbA1c.
- 9 March 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 90
The association between triglyceride glucose index and changes in carotid intima-media thickness: a 6-year prospective study in the 4C cohort
- 9 March 2026
- Published by Springer Nature in Endocrine
- Vol. 91 (1) , 90
The association between triglyceride glucose index and changes in carotid intima-media thickness: a 6-year prospective study in the 4C cohort
- Open Access
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
miR‐221/222 Facilitate Pituitary Adenoma Progression Via PHACTR4 Downregulation
Most of pituitary adenomas are biologically benign, but some grow local‐invasively and can invade important adjacent tissues, resulting in clinical symptoms such as hormone secretion disorders and visual field defects. MicroRNA‐221/222 (miR‐221/222) is tandemly encoded on the X chromosome in humans, mice and rats, and is highly conserved in vertebrates with the same seed sequence. To date, miR‐221/222 has been reported as either a tumor suppressor or a tumor promoter in different tumors, however, its role in pituitary tumors has not been elucidated. Our study aimed to investigate the effect and mechanism of miRNA‐221/222 in pituitary tumor cells. Results of real‐time quantitative PCR showed that the expression level of miRNA‐221/222 in plasma exosomes from patients with pituitary tumor was significantly higher than that from healthy people. Results of cell function experiments indicated that miRNA‐221/222 significantly promoted cell proliferation and migration, inhibited apoptosis and significantly inhibited the expression of Cleaved‐Caspase3 and E‐cadherin, while promoted the expression level of N‐cadherin. With transcriptome sequencing and comprehensive bioinformatics analysis, PHACTR4 was identified as the potential target gene of miRNA‐221/222 in regulating biological functions of pituitary adenoma cells. Dual luciferase reporter assay confirmed that PHACTR4 was the direct target gene of miRNA‐221/222 and overexpression of PHACTR4 gene reversed the regulatory effects of miRNA‐221/222. In vivo experiment of subcutaneous tumor formation in nude mice verified that miRNA‐221/222 promoted tumor growth by targeting PHACTR4. In conclusion, miRNA‐221/222 played the role of proto‐oncogene in the occurrence and development of pituitary tumors by targeting PHACTR4, which provided a new target for the diagnosis and molecular treatment of pituitary adenomas.
- 1 January 2026
- Published by Wiley in Human Mutation
- Vol. 2026 (1)
Open AccessmiR‐221/222 Facilitate Pituitary Adenoma Progression Via PHACTR4 Downregulation
Most of pituitary adenomas are biologically benign, but some grow local‐invasively and can invade important adjacent tissues, resulting in clinical symptoms such as hormone secretion disorders and visual field defects. MicroRNA‐221/222 (miR‐221/222) is tandemly encoded on the X chromosome in humans, mice and rats, and is highly conserved in vertebrates with the same seed sequence. To date, miR‐221/222 has been reported as either a tumor suppressor or a tumor promoter in different tumors, however, its role in pituitary tumors has not been elucidated. Our study aimed to investigate the effect and mechanism of miRNA‐221/222 in pituitary tumor cells. Results of real‐time quantitative PCR showed that the expression level of miRNA‐221/222 in plasma exosomes from patients with pituitary tumor was significantly higher than that from healthy people. Results of cell function experiments indicated that miRNA‐221/222 significantly promoted cell proliferation and migration, inhibited apoptosis and significantly inhibited the expression of Cleaved‐Caspase3 and E‐cadherin, while promoted the expression level of N‐cadherin. With transcriptome sequencing and comprehensive bioinformatics analysis, PHACTR4 was identified as the potential target gene of miRNA‐221/222 in regulating biological functions of pituitary adenoma cells. Dual luciferase reporter assay confirmed that PHACTR4 was the direct target gene of miRNA‐221/222 and overexpression of PHACTR4 gene reversed the regulatory effects of miRNA‐221/222. In vivo experiment of subcutaneous tumor formation in nude mice verified that miRNA‐221/222 promoted tumor growth by targeting PHACTR4. In conclusion, miRNA‐221/222 played the role of proto‐oncogene in the occurrence and development of pituitary tumors by targeting PHACTR4, which provided a new target for the diagnosis and molecular treatment of pituitary adenomas.
- Open Access
- 14 October 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 242-255
Efficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study
Aims: To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by β‐cell function in exploratory analyses of the Soli‐D study. Materials and Methods: Soli‐D was a 24‐week, multicentre, randomised, open‐label study in Chinese adults with uncontrolled type 2 diabetes (T2D) on oral antidiabetic drugs (OADs). We evaluated glycaemic efficacy, body weight, total insulin daily dose and hypoglycaemia outcomes with iGlarLixi versus IDegAsp by baseline fasting C‐peptide and Homeostasis Model Assessment of β‐cell function (HOMA‐β) quartile measurements. Results: Among 386 participants, change in glycated haemoglobin (HbA1c), fasting plasma glucose or postprandial glucose at Week 24 showed no interaction with fasting C‐peptide or HOMA‐β quartile. The difference in HbA1c change favoured iGlarLixi versus IDegAsp in fasting C‐peptide quartile 1 (Q1; p = 0.045) and Q2 ( p = 0.023) and HOMA‐β Q1 ( p = 0.025). The proportion of participants with HbA1c p = 0.009) and HOMA‐β Q1 ( p = 0.013). Body weight benefits were observed with iGlarLixi in HOMA‐β Q1 ( p = 0.003). Total insulin daily dose was lower with iGlarLixi, showing interactions between C‐peptide or HOMA‐β quartile and insulin dose (U or U/kg; p int p = 0.040 and 0.037). Conclusions: iGlarLixi provides improved glycaemic control at lower insulin daily doses compared with IDegAsp, regardless of C‐peptide or HOMA‐β levels, in Chinese people with uncontrolled T2D on OADs.
- 14 October 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (1) , 242-255
Open AccessEfficacy and safety of iGlarLixi versus IDegAsp by baseline β‐cell function in Chinese people with type 2 diabetes: Exploratory analyses of the Soli‐D study
Aims: To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by β‐cell function in exploratory analyses of the Soli‐D study. Materials and Methods: Soli‐D was a 24‐week, multicentre, randomised, open‐label study in Chinese adults with uncontrolled type 2 diabetes (T2D) on oral antidiabetic drugs (OADs). We evaluated glycaemic efficacy, body weight, total insulin daily dose and hypoglycaemia outcomes with iGlarLixi versus IDegAsp by baseline fasting C‐peptide and Homeostasis Model Assessment of β‐cell function (HOMA‐β) quartile measurements. Results: Among 386 participants, change in glycated haemoglobin (HbA1c), fasting plasma glucose or postprandial glucose at Week 24 showed no interaction with fasting C‐peptide or HOMA‐β quartile. The difference in HbA1c change favoured iGlarLixi versus IDegAsp in fasting C‐peptide quartile 1 (Q1; p = 0.045) and Q2 ( p = 0.023) and HOMA‐β Q1 ( p = 0.025). The proportion of participants with HbA1c p = 0.009) and HOMA‐β Q1 ( p = 0.013). Body weight benefits were observed with iGlarLixi in HOMA‐β Q1 ( p = 0.003). Total insulin daily dose was lower with iGlarLixi, showing interactions between C‐peptide or HOMA‐β quartile and insulin dose (U or U/kg; p int p = 0.040 and 0.037). Conclusions: iGlarLixi provides improved glycaemic control at lower insulin daily doses compared with IDegAsp, regardless of C‐peptide or HOMA‐β levels, in Chinese people with uncontrolled T2D on OADs.
- 19 April 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (6) , 1403-1414
Long-term cardiometabolic outcomes of primary bilateral macronodular adrenal hyperplasia
Purpose This study investigated long-term alterations in cardiometabolic comorbidities among patients with primary bilateral macronodular adrenal hyperplasia (PBMAH) who received surgical or conservative treatments. Methods A single-center, retrospective study analyzed 132 patients with PBMAH, divided into a surgery group (n = 68) and a control group (n = 64) based on treatment modalities. The main outcomes included changes in blood pressure (BP), blood glucose, lipids, and body weight. Results Among the 132 patients, hypertension, abnormal glucose metabolism, dyslipidemia, and overweight/obesity were prevalent in over 50% of cases. The surgery group demonstrated significantly greater improvements in BP, blood glucose, and weight control compared with the control group. Adrenalectomy was associated with enhanced BP control, blood glucose control, and at least one cardiometabolic risk factor control. In a group of 95 patients with mild autonomous cortisol secretion, the surgery group also exhibited higher rates of improvement in BP and blood glucose than the control group. Adrenalectomy was associated with improved BP, blood glucose, and at least one cardiometabolic risk factor. Conclusion Our study observed that most patients with PBMAH exhibited at least one cardiometabolic risk factor. Adrenalectomy was associated with improved BP and blood glucose for patients with PBMAH, including those with mild autonomous cortisol secretion.
- 19 April 2025
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 48 (6) , 1403-1414
Long-term cardiometabolic outcomes of primary bilateral macronodular adrenal hyperplasia
Purpose This study investigated long-term alterations in cardiometabolic comorbidities among patients with primary bilateral macronodular adrenal hyperplasia (PBMAH) who received surgical or conservative treatments. Methods A single-center, retrospective study analyzed 132 patients with PBMAH, divided into a surgery group (n = 68) and a control group (n = 64) based on treatment modalities. The main outcomes included changes in blood pressure (BP), blood glucose, lipids, and body weight. Results Among the 132 patients, hypertension, abnormal glucose metabolism, dyslipidemia, and overweight/obesity were prevalent in over 50% of cases. The surgery group demonstrated significantly greater improvements in BP, blood glucose, and weight control compared with the control group. Adrenalectomy was associated with enhanced BP control, blood glucose control, and at least one cardiometabolic risk factor control. In a group of 95 patients with mild autonomous cortisol secretion, the surgery group also exhibited higher rates of improvement in BP and blood glucose than the control group. Adrenalectomy was associated with improved BP, blood glucose, and at least one cardiometabolic risk factor. Conclusion Our study observed that most patients with PBMAH exhibited at least one cardiometabolic risk factor. Adrenalectomy was associated with improved BP and blood glucose for patients with PBMAH, including those with mild autonomous cortisol secretion.
- Open Access
- 11 March 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (5) , 2540-2551
Efficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
Aim: To evaluate the efficacy and safety of semaglutide 2.4 mg versus placebo for weight management in a population of Chinese adults with overweight or obesity. Materials and Methods: In STEP 7 (NCT04251156), a double‐blind, phase 3a trial, adults from a predominantly East Asian population with overweight or obesity, with or without type 2 diabetes, were randomized 2:1 to once‐weekly subcutaneous semaglutide 2.4 mg or placebo for 44 weeks as an adjunct to a reduced‐calorie diet and increased physical activity. This prespecified analysis evaluated Chinese participants in STEP 7. The primary endpoints were percentage change in body weight from baseline to Week 44 and the proportion of participants who achieved ≥5% reduction in body weight from baseline. Results: Overall, 195 Chinese participants were randomized to semaglutide 2.4 mg and 105 to placebo. Estimated change in mean body weight from baseline to Week 44 was −11.8% with semaglutide 2.4 mg versus −3.5% with placebo (estimated treatment difference −8.3%; 95% confidence interval [CI] –10.2, −6.4; p < 0.0001). At Week 44, a greater proportion of participants treated with semaglutide 2.4 mg achieved ≥5% body weight loss versus placebo (85.4% vs. 26.8%): odds ratio 16.1; 95% CI 8.4, 30.9; p < 0.0001. Adverse events were reported by 92.3% of semaglutide‐treated participants and 82.9% of placebo‐treated participants, the most common of which were gastrointestinal disorders (126/195, 64.6% vs. 35/105, 33.3%). Conclusions: These data demonstrate beneficial effects of semaglutide 2.4 mg versus placebo, supporting its use in an adult Chinese population with overweight or obesity.
- 11 March 2025
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 27 (5) , 2540-2551
Open AccessEfficacy and safety of once‐weekly semaglutide 2.4 mg for weight management in participants from China: A prespecified analysis of the STEP 7 randomized clinical trial
Aim: To evaluate the efficacy and safety of semaglutide 2.4 mg versus placebo for weight management in a population of Chinese adults with overweight or obesity. Materials and Methods: In STEP 7 (NCT04251156), a double‐blind, phase 3a trial, adults from a predominantly East Asian population with overweight or obesity, with or without type 2 diabetes, were randomized 2:1 to once‐weekly subcutaneous semaglutide 2.4 mg or placebo for 44 weeks as an adjunct to a reduced‐calorie diet and increased physical activity. This prespecified analysis evaluated Chinese participants in STEP 7. The primary endpoints were percentage change in body weight from baseline to Week 44 and the proportion of participants who achieved ≥5% reduction in body weight from baseline. Results: Overall, 195 Chinese participants were randomized to semaglutide 2.4 mg and 105 to placebo. Estimated change in mean body weight from baseline to Week 44 was −11.8% with semaglutide 2.4 mg versus −3.5% with placebo (estimated treatment difference −8.3%; 95% confidence interval [CI] –10.2, −6.4; p < 0.0001). At Week 44, a greater proportion of participants treated with semaglutide 2.4 mg achieved ≥5% body weight loss versus placebo (85.4% vs. 26.8%): odds ratio 16.1; 95% CI 8.4, 30.9; p < 0.0001. Adverse events were reported by 92.3% of semaglutide‐treated participants and 82.9% of placebo‐treated participants, the most common of which were gastrointestinal disorders (126/195, 64.6% vs. 35/105, 33.3%). Conclusions: These data demonstrate beneficial effects of semaglutide 2.4 mg versus placebo, supporting its use in an adult Chinese population with overweight or obesity.
- 5 January 2025
- Published by Elsevier in Cancer Letters
- Vol. 611, 217443
Role of Cathepsin K in bone invasion of pituitary adenomas: A dual mechanism involving cell proliferation and osteoclastogenesis
- 5 January 2025
- Published by Elsevier in Cancer Letters
- Vol. 611, 217443
Role of Cathepsin K in bone invasion of pituitary adenomas: A dual mechanism involving cell proliferation and osteoclastogenesis
- 9 October 2024
- Published by Springer Nature in Endocrine
- Vol. 87 (2) , 810-821
Long-term outcome of unilateral adrenalectomy for primary bilateral macronodular adrenal hyperplasia
Purpose Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a form of Cushing’s syndrome (CS) characterized by heterogeneous cortisol secretion and clinical comorbidities. Previously, bilateral adrenalectomy was the standard treatment for PBMAH, but this approach carried a high risk of primary adrenocortical insufficiency. In recent decades, unilateral adrenalectomy (U-Adx) has emerged as an effective alternative. However, limited research exists on its postoperative efficacy and prognostic predictors. Therefore, the present study aimed to investigate the long-term effectiveness and prognostic predictors of U-Adx in treating PBMAH. Methods A total of 61 patients with PBMAH diagnosis who underwent U-Adx at a single center between 2004 and 2022 were retrospectively evaluated. Patients were categorized into persistent hypercortisolism and remission groups based on postoperative biochemical outcomes at the last follow-up (>12 months after U-Adx). Clinical characteristics, comorbidities, plasma adrenocorticotropic hormone (ACTH), serum cortisol, and 24-h urinary-free cortisol (24-h UFC) levels were analyzed pre- and postoperatively. We further examined whether baseline plasma ACTH, serum cortisol, 24-h UFC levels, and the inhibition of cortisol and 24-h UFC after a low-dose dexamethasone suppression test (LDDST) could predict non-remission following U-Adx. Additionally, we explored the improvements in hypertension, abnormal glucose metabolism, osteoporosis, and other complications in patients with PBMAH post-U-Adx. Results After U-Adx, 22 of the 45 patients (48.89%) achieved initial remission within 6 months. At the last follow-up, 25 of the 45 patients underwent all required biochemical tests and cortisol assessment tests, among which eight of 25 (32.00%) were in remission and 17 of 25 (68.00%) were experiencing persistent hypercortisolism. Moreover, five of those 25 patients exhibited recurrence after initial remission. Baseline 24-h UFC level > 2 times the upper limit of normal (2ULN) and unsuppressed 24-h UFC after LDDST may predict persistent hypercortisolism postoperatively. Lastly, long-term postoperative follow-up revealed that hypertension decreased with hypercortisolism remission, whereas osteoporosis worsened with persistent hypercortisolism. Conclusion The short-term remission rate of hypercortisolism was 48.89% in patients with PBMAH treated with U-Adx, while a long-term remission rate of 32.00% was achieved after a median follow-up of 38.58 months. Furthermore, this finding suggests that baseline 24-h UFC level > 2ULN and unsuppressed 24-h UFC after LDDST predict persistent hypercortisolism in the long-term post-U-Adx. Finally, U-Adx improved cortisol circadian rhythm alterations and ACTH suppression in the patients in the remission group, thereby substantially alleviating hypertension and delaying the development of osteoporosis linked to PBMAH.
- 9 October 2024
- Published by Springer Nature in Endocrine
- Vol. 87 (2) , 810-821
Long-term outcome of unilateral adrenalectomy for primary bilateral macronodular adrenal hyperplasia
Purpose Primary bilateral macronodular adrenal hyperplasia (PBMAH) is a form of Cushing’s syndrome (CS) characterized by heterogeneous cortisol secretion and clinical comorbidities. Previously, bilateral adrenalectomy was the standard treatment for PBMAH, but this approach carried a high risk of primary adrenocortical insufficiency. In recent decades, unilateral adrenalectomy (U-Adx) has emerged as an effective alternative. However, limited research exists on its postoperative efficacy and prognostic predictors. Therefore, the present study aimed to investigate the long-term effectiveness and prognostic predictors of U-Adx in treating PBMAH. Methods A total of 61 patients with PBMAH diagnosis who underwent U-Adx at a single center between 2004 and 2022 were retrospectively evaluated. Patients were categorized into persistent hypercortisolism and remission groups based on postoperative biochemical outcomes at the last follow-up (>12 months after U-Adx). Clinical characteristics, comorbidities, plasma adrenocorticotropic hormone (ACTH), serum cortisol, and 24-h urinary-free cortisol (24-h UFC) levels were analyzed pre- and postoperatively. We further examined whether baseline plasma ACTH, serum cortisol, 24-h UFC levels, and the inhibition of cortisol and 24-h UFC after a low-dose dexamethasone suppression test (LDDST) could predict non-remission following U-Adx. Additionally, we explored the improvements in hypertension, abnormal glucose metabolism, osteoporosis, and other complications in patients with PBMAH post-U-Adx. Results After U-Adx, 22 of the 45 patients (48.89%) achieved initial remission within 6 months. At the last follow-up, 25 of the 45 patients underwent all required biochemical tests and cortisol assessment tests, among which eight of 25 (32.00%) were in remission and 17 of 25 (68.00%) were experiencing persistent hypercortisolism. Moreover, five of those 25 patients exhibited recurrence after initial remission. Baseline 24-h UFC level > 2 times the upper limit of normal (2ULN) and unsuppressed 24-h UFC after LDDST may predict persistent hypercortisolism postoperatively. Lastly, long-term postoperative follow-up revealed that hypertension decreased with hypercortisolism remission, whereas osteoporosis worsened with persistent hypercortisolism. Conclusion The short-term remission rate of hypercortisolism was 48.89% in patients with PBMAH treated with U-Adx, while a long-term remission rate of 32.00% was achieved after a median follow-up of 38.58 months. Furthermore, this finding suggests that baseline 24-h UFC level > 2ULN and unsuppressed 24-h UFC after LDDST predict persistent hypercortisolism in the long-term post-U-Adx. Finally, U-Adx improved cortisol circadian rhythm alterations and ACTH suppression in the patients in the remission group, thereby substantially alleviating hypertension and delaying the development of osteoporosis linked to PBMAH.